While rare, serious adverse effects including euglycemic diabetic ketoacidosis (EDKA) have been associated with sodium-glucose cotransporter-2 inhibitor (SGLT2i) use. We present an interesting case of SGLT2i-induced EDKA occurring two years after initiation of therapy. Most patients with EDKA recover with prompt recognition and treatment. Patient education about identifying early signs remains a cornerstone of early identification and response to SGLT2i-induced EDKA.
Keywords: diabetic keto acidosis; euglycemic dka; high anion gap metabolic acidosis; sglt-2 inhibitor; sodium-glucose cotransporter-2 inhibitors.
Copyright © 2022, Rao et al.